IL13 and COVID-19: As HA has been demonstrated as a mediator of multiple pulmonary diseases, including pulmonary fibrosis and idiopathic pulmonary hypertension [15], this led to the hypothesis that IL-13, acting as a regulator of HA matrix formation, may be involved in pulmonary dysfunction after recovery from COVID-19 [16].